{"id":7724,"date":"2025-07-01T20:31:46","date_gmt":"2025-07-01T12:31:46","guid":{"rendered":"https:\/\/allcancer.com\/cancer\/chronic-myelogenous-leukemia-cml-2\/"},"modified":"2025-07-02T19:34:49","modified_gmt":"2025-07-02T11:34:49","slug":"%e6%85%a2%e6%80%a7%e9%aa%a8%e9%ab%93%e6%80%a7%e7%99%bd%e8%a1%80%e7%97%85-cml-%e7%99%8c%e7%97%87%e9%a1%9e%e5%9e%8b","status":"publish","type":"cancer_type","link":"https:\/\/allcancer.com\/hk\/%e7%99%8c%e7%97%87\/%e6%85%a2%e6%80%a7%e9%aa%a8%e9%ab%93%e6%80%a7%e7%99%bd%e8%a1%80%e7%97%85-cml-%e7%99%8c%e7%97%87%e9%a1%9e%e5%9e%8b\/","title":{"rendered":"\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)"},"content":{"rendered":"

\u4ec0\u9ebc\u662f \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong>?<\/h2>\n

\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)\uff0c\u4e5f\u7a31\u70ba\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff0c\u662f\u4e00\u7a2e\u8d77\u6e90\u65bc\u9aa8\u9ad3\u7684\u764c\u75c7\uff0c\u8207\u6025\u6027\u767d\u8840\u75c5\u76f8\u6bd4\uff0c\u9032\u5c55\u7de9\u6162\u3002\u8207\u5176\u4ed6\u5f62\u5f0f\u7684\u767d\u8840\u75c5\u4e0d\u540c\uff0cCML \u901a\u5e38\u6703\u5f71\u97ff\u6210\u719f\u7684\u9ad3\u7d30\u80de\uff0c\u9ad3\u7d30\u80de\u662f\u8ca0\u8cac\u4fdd\u8b77\u8eab\u9ad4\u514d\u53d7\u611f\u67d3\u7684\u4e00\u985e\u8840\u7d30\u80de\u3002\u96a8\u8457\u6642\u9593\u7684\u63a8\u79fb\uff0c\u9019\u4e9b\u7570\u5e38\u7d30\u80de\u6703\u904e\u5ea6\u7d2f\u7a4d\uff0c\u6392\u64e0\u5065\u5eb7\u7684\u8840\u7d30\u80de\uff0c\u9020\u6210\u56b4\u91cd\u7684\u5065\u5eb7\u554f\u984c\u3002<\/p>\n

\u751f\u7269\u57fa\u790e\u548c\u4ee3\u8b1d\u8106\u5f31\u6027<\/h3>\n

\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6838\u5fc3\u75c5\u56e0\u662f\u4e00\u7a2e\u7a31\u70ba\u8cbb\u57ce\u67d3\u8272\u9ad4\u7684\u907a\u50b3\u7570\u5e38\u3002\u9019\u7a2e\u7570\u5e38\u662f\u7531\u65bc 9 \u865f\u8207 22 \u865f\u67d3\u8272\u9ad4\u4e4b\u9593\u7684\u6613\u4f4d\uff08\u907a\u50b3\u7269\u8cea\u7684\u4ea4\u63db\uff09\u6240\u5c0e\u81f4\u3002\u9019\u7a2e\u57fa\u56e0\u7a81\u8b8a\u6703\u7522\u751f\u4e00\u7a2e\u7a31\u70ba BCR-ABL \u7684\u878d\u5408\u57fa\u56e0\uff0c\u8ca0\u8cac\u916a\u6c28\u9178\u6fc0\u9176\u7684\u904e\u5ea6\u6d3b\u6027\uff0c\u5c0e\u81f4\u9aa8\u9ad3\u7d30\u80de\u4e0d\u53d7\u63a7\u5236\u5730\u589e\u6b96\u3002<\/p>\n

\u9664\u4e86\u9019\u7a2e\u57fa\u56e0\u57fa\u790e\u4e4b\u5916\uff0c\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u764c\u7d30\u80de\u4e5f\u5c55\u73fe\u51fa\u7368\u7279\u7684\u4ee3\u8b1d\u884c\u70ba\u3002\u5176\u4e2d\u4e00\u500b\u4ee3\u8b1d\u7279\u5fb5\u662f\u6c83\u4f2f\u683c\u6548\u61c9\uff0c\u764c\u7d30\u80de\u5373\u4f7f\u5728\u6709\u6c27\u7684\u60c5\u6cc1\u4e0b\uff0c\u4e5f\u6703\u900f\u904e\u7cd6\u9175\u89e3\u512a\u5148\u5229\u7528\u8461\u8404\u7cd6\u3002\u4e8b\u5be6\u4e0a\uff0cCML \u7684\u764c\u7d30\u80de\u6d88\u8017\u8461\u8404\u7cd6\u7684\u901f\u5ea6\u6bd4\u5065\u5eb7\u7d30\u80de\u9ad8\u7d04 200 \u500d\u3002\u9019\u7a2e\u5c0d\u8461\u8404\u7cd6\u65b0\u9673\u4ee3\u8b1d\u7684\u9ad8\u5ea6\u4f9d\u8cf4\u69cb\u6210\u4e86\u4e00\u500b\u91cd\u8981\u7684\u5f31\u9ede\uff0c\u65b0\u9673\u4ee3\u8b1d\u816b\u7624\u5b78\u6cbb\u7642\u7b49\u5c16\u7aef\u7642\u6cd5\u5c31\u662f\u8981\u5229\u7528\u9019\u500b\u5f31\u9ede\u3002<\/p>\n

    \n
  • \u6c83\u4f2f\u683c\u6548\u61c9\u764c\u7d30\u80de\u975e\u5e38\u4f9d\u8cf4\u5feb\u901f\u651d\u53d6\u8461\u8404\u7cd6\u548c\u4e19\u916e\u9178\u767c\u9175\uff0c\u7522\u751f\u4e73\u9178\u4ee5\u652f\u6301\u5176\u5feb\u901f\u6210\u9577\u3002<\/li>\n
  • \u8c37\u6c28\u9170\u80fa\u4f9d\u8cf4\u6027\u589e\u52a0\uff1a\u7d04\u6709 50% \u7684\u764c\u7d30\u80de (\u5305\u62ec\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u764c\u7d30\u80de) \u4f9d\u8cf4 Glutamine \u4ee3\u8b1d\u4f86\u63d0\u4f9b\u80fd\u91cf\u548c\u5408\u6210\u6838\u82f7\u9178\u3002<\/li>\n
  • \u6cbb\u7642\u76ee\u6a19\uff1a\u5229\u7528\u65b0\u9673\u4ee3\u8b1d\u7684\u5f31\u9ede\u6709\u6548\u5730\u64fe\u4e82\u764c\u7d30\u80de\u7684\u589e\u6b96\u3002<\/li>\n<\/ul>\n

    \u4e86\u89e3\u9019\u4e9b\u65b0\u9673\u4ee3\u8b1d\u7684\u5f31\u9ede\uff0c\u5df2\u70ba\u6cbb\u7642\u7b56\u7565\u5e36\u4f86\u9769\u547d\u6027\u7684\u6539\u8b8a\uff0c\u5f9e\u800c\u7814\u767c\u51fa\u5275\u65b0\u7684\u7642\u6cd5\uff0c\u4f8b\u5982\u6211\u5011\u5c08\u5229\u7684 HK Metabolic Therapy\uff0c\u5c08\u9580\u91dd\u5c0d\u764c\u75c7\u7d30\u80de\u7684\u65b0\u9673\u4ee3\u8b1d\u800c\u8a2d\u8a08\uff0c\u9054\u5230\u63d0\u5347\u75c5\u4eba\u7642\u6548\u7684\u76ee\u7684\u3002<\/p>\n

    \u6d41\u884c\u7387\u548c\u4eba\u53e3\u7d71\u8a08\uff1a\u4ee5\u9999\u6e2f\u548c\u4e9e\u6d32\u70ba\u91cd\u9ede<\/h3>\n

    \u5168\u7403\u767d\u8840\u75c5\u7684\u767c\u75c5\u7387\u76f8\u7576\u9ad8\uff0c\u6bcf\u5e74\u6709\u6578\u4ee5\u5343\u8a08\u7684\u60a3\u8005\u88ab\u8a3a\u65b7\u51fa\u60a3\u6709\u767d\u8840\u75c5\u3002\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7d04\u4f54\u6240\u6709\u6210\u4eba\u767d\u8840\u75c5\u7684 15-20%\u3002\u6839\u64da\u4e16\u754c\u885b\u751f\u7d44\u7e54 2024 \u5e74\u7684\u5831\u544a\uff0c\u5168\u7403\u767d\u8840\u75c5\u7684\u767c\u75c5\u7387\u6b63\u7a69\u6b65\u4e0a\u5347\uff0c\u4f30\u8a08\u6bcf\u5e74\u7d04\u6709 500,000 \u500b\u65b0\u75c5\u4f8b\u3002\u5728\u5305\u62ec\u9999\u6e2f\u5728\u5167\u7684\u4e9e\u6d32\u5730\u5340\uff0c\u7531\u65bc\u4eba\u53e3\u8001\u5316\u3001\u74b0\u5883\u6c59\u67d3\u7269\u589e\u52a0\u4ee5\u53ca\u907a\u50b3\u50be\u5411\u7b49\u56e0\u7d20\u7684\u5f71\u97ff\uff0c\u767d\u8840\u75c5\u7684\u767c\u75c5\u7387\u5c24\u5176\u4ee4\u4eba\u64d4\u6182\u3002<\/p>\n

      \n
    • \u5e74\u9f61\u5206\u4f48\uff1a\u5927\u591a\u6578\u60a3\u8005\u7684\u8a3a\u65b7\u5e74\u9f61\u4ecb\u65bc 50-70 \u6b72\u4e4b\u9593\uff0c\u4e0d\u904e\u5e74\u8f15\u7684\u60a3\u8005\u4e5f\u53ef\u80fd\u53d7\u5f71\u97ff\u3002<\/li>\n
    • \u6027\u5225\u5f71\u97ff\uff1a\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u75c5\u4f8b\u4e2d\u5df2\u89c0\u5bdf\u5230\u8f15\u5fae\u7684\u7537\u6027\u512a\u5148\u3002<\/li>\n
    • \u7279\u5b9a\u5730\u5340\u7684\u98a8\u96aa\uff1a\u5728\u4eba\u53e3\u7a20\u5bc6\u7684\u4e9e\u6d32\u5730\u5340\uff08\u5305\u62ec\u9999\u6e2f\uff09\uff0c\u7a7a\u6c23\u6c61\u67d3\u3001\u63a5\u89f8\u5316\u5b78\u7269\u8cea\u548c\u8077\u696d\u5371\u5bb3\u6703\u5c0e\u81f4\u767d\u8840\u75c5\u767c\u75c5\u7387\u589e\u52a0\u3002<\/li>\n<\/ul>\n

      \u9999\u6e2f\u4eba\u53e3\u5bc6\u5ea6\u9ad8\uff0c\u52a0\u4e0a\u63a5\u89f8\u6c61\u67d3\u7269\u7684\u6a5f\u6703\u589e\u52a0\uff0c\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u5df2\u6210\u70ba\u516c\u5171\u885b\u751f\u7684\u95dc\u6ce8\u7126\u9ede\u3002\u6b64\u5916\uff0c\u5c0d\u6162\u6027\u7c92\u7d30\u80de\u767d\u8840\u75c5\u7684\u8a8d\u8b58\u4e0d\u8db3\u548c\u5ef6\u9072\u8a3a\u65b7\u5f80\u5f80\u6703\u5c0e\u81f4\u75c5\u60c5\u66f4\u52a0\u56b4\u91cd\uff0c\u56e0\u6b64\u6709\u5fc5\u8981\u9032\u884c\u5354\u8abf\u4e00\u81f4\u7684\u6559\u80b2\u548c\u7be9\u67e5\u5de5\u4f5c\u3002<\/p>\n

      \u60c5\u7dd2\u548c\u8eab\u9ad4\u5f71\u97ff<\/h3>\n

      \u88ab\u8a3a\u65b7\u51fa\u7f79\u60a3\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u60a3\u8005\u6703\u7d93\u6b77\u56b4\u91cd\u7684\u8eab\u5fc3\u969c\u7919\u3002\u5305\u62ec\u75b2\u52de\u3001\u4e0d\u660e\u539f\u56e0\u7684\u9ad4\u91cd\u4e0b\u964d\u3001\u76dc\u6c57\u4ee5\u53ca\u56e0\u813e\u816b\u5927\u800c\u5f15\u8d77\u7684\u8179\u90e8\u4e0d\u9069\u7b49\u75c7\u72c0\uff0c\u90fd\u6703\u56b4\u91cd\u640d\u5bb3\u60a3\u8005\u7684\u751f\u6d3b\u54c1\u8cea\u3002\u60c5\u7dd2\u4e0a\u7684\u65c5\u7a0b\u4e5f\u540c\u6a23\u5145\u6eff\u6311\u6230\uff0c\u7126\u616e\u3001\u6cae\u55aa\u548c\u5c0d\u672a\u4f86\u7684\u4e0d\u78ba\u5b9a\u611f\u662f\u5e38\u898b\u7684\u60c5\u7dd2\u554f\u984c\u3002<\/p>\n

      \u5728 AllCancer\uff0c\u6211\u5011\u7684\u5168\u9762\u7167\u8b77\u6a21\u5f0f\u5f37\u8abf\u5728\u5148\u9032\u6cbb\u7642\u7684\u540c\u6642\u63d0\u4f9b\u9ad4\u8cbc\u7684\u652f\u63f4\uff0c\u76ee\u6a19\u4e0d\u50c5\u662f\u7de9\u89e3\u75c5\u60c5\uff0c\u9084\u8981\u6539\u5584\u60a3\u8005\u7684\u60c5\u7dd2\u548c\u751f\u6d3b\u54c1\u8cea\u3002<\/p>\n

      \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6210\u56e0\u8207\u98a8\u96aa\u56e0\u7d20<\/h2>\n

      1.\u907a\u50b3\u56e0\u7d20\u8207\u7a81\u8b8a<\/h3>\n

      \u8cbb\u57ce\u67d3\u8272\u9ad4\u7b49\u907a\u50b3\u7a81\u8b8a\u7684\u9451\u5b9a\u662f\u8a3a\u65b7\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u57fa\u77f3\u3002\u9019\u7a2e\u67d3\u8272\u9ad4\u6613\u4f4d\u6703\u7522\u751f BCR-ABL \u878d\u5408\u86cb\u767d\uff0c\u9020\u6210\u9ad3\u7d30\u80de\u7121\u7bc0\u5236\u5730\u751f\u9577\u548c\u589e\u6b96\u3002\u4e86\u89e3\u9019\u4e9b\u57fa\u56e0\u7a81\u8b8a\u6709\u52a9\u65bc\u65e9\u671f\u8a3a\u65b7\u3001\u9810\u5f8c\u8a55\u4f30\u548c\u91dd\u5c0d\u6027\u6cbb\u7642\u5e72\u9810\u3002<\/p>\n

        \n
      • \u8cbb\u57ce\u67d3\u8272\u9ad4\uff1a\u51fa\u73fe\u5728 90-95% \u7684 CML \u75c5\u4f8b\u4e2d\u3002<\/li>\n
      • \u5176\u4ed6\u57fa\u56e0\u7a81\u8b8a\uff1a\u7f55\u898b\u7684\u57fa\u56e0\u7a81\u8b8a\u53ef\u80fd\u6703\u5f71\u97ff\u75be\u75c5\u7684\u767c\u5c55\u548c\u5c0d\u6cbb\u7642\u7684\u53cd\u61c9\uff0c\u56e0\u6b64\u57fa\u56e0\u6aa2\u6e2c\u5728\u500b\u4eba\u5316\u6cbb\u7642\u4e2d\u81f3\u95dc\u91cd\u8981\u3002<\/li>\n<\/ul>\n

        2.\u74b0\u5883\u8207\u8077\u696d\u56e0\u7d20<\/h3>\n

        \u9577\u671f\u66b4\u9732\u65bc\u7279\u5b9a\u7684\u74b0\u5883\u548c\u5de5\u696d\u5316\u5b78\u7269\u8cea (\u4f8b\u5982\u5ee3\u6cdb\u5b58\u5728\u65bc\u5de5\u696d\u74b0\u5883\u4e2d\u7684\u82ef) \u6703\u986f\u8457\u589e\u52a0\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u98a8\u96aa\u3002\u4e9e\u6d32\u90fd\u6703\u5340\uff0c\u7279\u5225\u662f\u9999\u6e2f\uff0c\u7531\u65bc\u4ea4\u901a\u5bc6\u5ea6\u9ad8\u548c\u5de5\u696d\u6d3b\u52d5\u983b\u7e41\uff0c\u7d93\u5e38\u51fa\u73fe\u82ef\u548c\u7a7a\u6c23\u6c61\u67d3\u7269\u5347\u9ad8\u7684\u73fe\u8c61\u3002<\/p>\n

          \n
        • \u82ef\u63a5\u89f8\uff1a\u8207\u767d\u8840\u75c5\u767c\u75c5\u6709\u5bc6\u5207\u95dc\u4fc2\uff0c\u4fc3\u8acb\u5236\u5b9a\u66f4\u56b4\u683c\u7684\u8077\u696d\u4fdd\u8b77\u8207\u6cd5\u898f\u3002<\/li>\n
        • \u8f3b\u5c04\u66b4\u9732\uff1a\u66fe\u56e0\u5176\u4ed6\u60e1\u6027\u816b\u7624\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u80fd\u6703\u589e\u52a0\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u98a8\u96aa\u3002<\/li>\n
        • \u6c61\u67d3\uff1a\u90fd\u5e02\u74b0\u5883\u6c61\u67d3\u7269\u662f\u65b0\u8208\u7684\u98a8\u96aa\u56e0\u7d20\u3002<\/li>\n<\/ul>\n

          3.\u751f\u6d3b\u65b9\u5f0f\u76f8\u95dc\u56e0\u7d20<\/h3>\n

          \u751f\u6d3b\u65b9\u5f0f\u56e0\u7d20\u8207\u767d\u8840\u75c5 (\u5305\u62ec\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)) \u7684\u95dc\u4fc2\u65e5\u76ca\u5bc6\u5207\u3002\u80a5\u80d6\u3001\u6162\u6027\u98f2\u98df\u767c\u708e\u548c\u5438\u7159\u8207\u98a8\u96aa\u986f\u8457\u5347\u9ad8\u6709\u95dc\uff0c\u9019\u53ef\u80fd\u662f\u7531\u65bc\u9577\u671f\u7684\u65b0\u9673\u4ee3\u8b1d\u58d3\u529b\u548c\u6162\u6027\u767c\u708e\u5f71\u97ff\u4e86\u7d30\u80de\u7684\u8abf\u7bc0\u904e\u7a0b\u3002\u77ad\u89e3\u9019\u4e9b\u53ef\u6539\u8b8a\u7684\u98a8\u96aa\u53ef\u8b93\u500b\u4eba\u7a4d\u6975\u964d\u4f4e\u7f79\u60a3\u767d\u8840\u75c5\u7684\u53ef\u80fd\u6027\u3002<\/p>\n

            \n
          • \u80a5\u80d6\u75c7\uff1a\u904e\u91cd\u7684\u9ad4\u91cd\u6703\u56e0\u9577\u671f\u767c\u708e\u548c\u65b0\u9673\u4ee3\u8b1d\u7d0a\u4e82\u800c\u589e\u52a0\u7f79\u60a3\u764c\u75c7\u7684\u98a8\u96aa\u3002<\/li>\n
          • \u5438\u7159\uff1a\u73fe\u6709\u8b49\u64da\u986f\u793a\uff0c\u5438\u7159\u7fd2\u6163\u8207\u767d\u8840\u75c5\u767c\u751f\u7387\u5347\u9ad8\u6709\u95dc\uff0c\u5c24\u5176\u5c0d\u5f8c\u679c\u6709\u8ca0\u9762\u5f71\u97ff\u3002<\/li>\n
          • \u6162\u6027\u767c\u708e\uff1a\u9577\u671f\u767c\u708e\u53ef\u80fd\u6703\u4fc3\u9032\u8106\u5f31\u7d30\u80de\u7fa4\u7684\u764c\u75c7\u8f49\u5316\u3002<\/li>\n<\/ul>\n

            \u5728 AllCancer\uff0c\u9810\u9632\u7b56\u7565\u548c\u6559\u80b2\u6d3b\u52d5\u4f7f\u5168\u6e2f\u7684\u60a3\u8005\u80fd\u5920\u900f\u904e\u8abf\u6574\u751f\u6d3b\u65b9\u5f0f\u548c\u5168\u9762\u7be9\u6aa2\uff0c\u6e1b\u5c11\u53ef\u6539\u8b8a\u7684\u98a8\u96aa\u56e0\u7d20\u3002\u53ca\u65e9\u8b58\u5225\u98a8\u96aa\u56e0\u7d20\u4e26\u914d\u5408\u4ee3\u8b1d\u5e72\u9810\u65b9\u6cd5\uff0c\u53ef\u986f\u8457\u63d0\u9ad8\u60a3\u8005\u7684\u7642\u6548\u3002<\/p>\n

            \u7d50\u8ad6\uff1a\u65e9\u671f\u6aa2\u6e2c\u7684\u91cd\u8981\u6027<\/h3>\n

            \u5728\u6162\u6027\u7c92\u7d30\u80de\u767d\u8840\u75c5 (CML) \u7684\u65e9\u671f\u968e\u6bb5\u9451\u5b9a\u5176\u75c5\u75c7\uff0c\u5c0d\u65bc\u6210\u529f\u7684\u6cbb\u7642\u7d50\u679c\u4ecd\u81f3\u95dc\u91cd\u8981\u3002\u4ee3\u8b1d\u816b\u7624\u7642\u6cd5\u7684\u9032\u5c55\uff0c\u7279\u5225\u662f\u6211\u5011\u5c08\u9580\u7684 HK \u4ee3\u8b1d\u7642\u6cd5\uff0c\u5df2\u5927\u5927\u6539\u8b8a\u4e86\u75c5\u60a3\u7684\u9810\u5f8c\uff0c\u63d0\u4f9b\u4e86\u9ad4\u6064\u3001\u91dd\u5c0d\u6027\u548c\u6709\u6548\u7684\u7ba1\u7406\u65b9\u6cd5\uff0c\u5e0c\u671b\u5c07\u767d\u8840\u75c5\u8f49\u8b8a\u70ba\u53ef\u63a7\u5236\u7684\u6162\u6027\u75be\u75c5\u3002<\/p>\n

            \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u75c7\u72c0<\/h2>\n

            \u77ad\u89e3 \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong> \u662f\u53ca\u6642\u4ecb\u5165\u548c\u6539\u5584\u9810\u5f8c\u7684\u95dc\u9375\u3002\u5118\u7ba1\u65e9\u671f\u75c7\u72c0\u53ef\u80fd\u5f88\u5fae\u5f31\u4e14\u6a21\u7cca\u4e0d\u6e05\uff0c\u4f46\u82e5\u80fd\u5bdf\u89ba\u6301\u7e8c\u7684\u75c7\u72c0\uff0c\u5c31\u80fd\u53ca\u65e9\u9032\u884c\u91ab\u7642\u8a55\u4f30\uff0c\u4e26\u986f\u8457\u6539\u5584\u7d50\u679c\u3002<\/p>\n

            \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u5e38\u898b\u75c7\u72c0<\/h3>\n
              \n
            • \u75b2\u52de\u548c\u6301\u7e8c\u6027\u75b2\u52de<\/li>\n
            • \u5bb9\u6613\u7600\u50b7\u6216\u4e0d\u660e\u539f\u56e0\u51fa\u8840<\/li>\n
            • \u4e0d\u660e\u539f\u56e0\u7684\u9ad4\u91cd\u4e0b\u964d\u6216\u98df\u6b32\u6e1b\u9000<\/li>\n
            • \u51fa\u6c57\u904e\u591a\uff0c\u5c24\u5176\u662f\u5728\u665a\u4e0a\uff08\u76dc\u6c57\uff09<\/li>\n
            • \u767c\u71d2\u548c\u767c\u51b7<\/li>\n
            • \u813e\u81df\u816b\u5927\u5f15\u8d77\u8179\u90e8\u8139\u6c23\u6216\u4e0d\u9069<\/li>\n
            • \u9aa8\u75db\u6216\u95dc\u7bc0\u4e0d\u9069<\/li>\n
            • \u84bc\u767d\u986f\u793a\u8ca7\u8840<\/li>\n<\/ul>\n

              \u57fa\u65bc\u75be\u75c5\u968e\u6bb5\u7684\u75c7\u72c0\u8b8a\u5316<\/h3>\n

              \u75be\u75c5\u75c7\u72c0\u901a\u5e38\u6703\u56e0\u75be\u75c5\u968e\u6bb5\u7684\u4e0d\u540c\u800c\u6709\u986f\u8457\u7684\u5dee\u7570\u3002 \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong>\uff0c\u53cd\u6620\u4e86\u816b\u7624\u751f\u7269\u5b78\u548c\u75be\u75c5\u9032\u7a0b\u7684\u57fa\u672c\u8b8a\u5316\uff1a<\/p>\n

                \n
              • \u6162\u6027\u968e\u6bb5\uff1a<\/strong> \u75c7\u72c0\u76f8\u5c0d\u8f15\u5fae\u6216\u9577\u6642\u9593\u7121\u75c7\u72c0\uff0c\u5076\u723e\u56e0\u813e\u5927\u800c\u51fa\u73fe\u8f15\u5fae\u75b2\u52de\u6216\u96f6\u661f\u8179\u90e8\u4e0d\u9069\u3002<\/li>\n
              • \u52a0\u901f\u968e\u6bb5\uff1a<\/strong> \u75b2\u52de\u611f\u589e\u52a0\u3001\u9ad4\u91cd\u660e\u986f\u6e1b\u8f15\u3001\u611f\u67d3\u66f4\u983b\u7e41\u3001\u8840\u5c0f\u677f\u8a08\u6578\u4e0b\u964d\u5c0e\u81f4\u660e\u986f\u7600\u50b7\u6216\u51fa\u8840\u3002<\/li>\n
              • \u7206\u70b8\u5371\u6a5f\u968e\u6bb5\uff1a<\/strong> \u56b4\u91cd\u7684\u611f\u67d3\u98a8\u96aa\u3001\u6975\u5ea6\u8ca7\u8840\u3001\u51fa\u8840\u767c\u4f5c\u589e\u52a0\u3001\u808c\u8089\u6216\u9aa8\u9abc\u75bc\u75db\uff0c\u53cd\u6620\u51fa\u672a\u6210\u719f\u7684\u767d\u8840\u75c5\u7d30\u80de\u6ef2\u5165\u9aa8\u9abc\u548c\u5668\u5b98\u3002<\/li>\n<\/ul>\n

                \u9019\u4e9b\u75c7\u72c0\u53cd\u6620\u4e86\u767d\u8840\u75c5\u7d30\u80de\u56fa\u6709\u7684\u5927\u91cf\u589e\u6b96\u6d3b\u52d5\u548c\u907a\u50b3\u4e0d\u7a69\u5b9a\u6027\uff0c\u7a81\u986f\u4e86\u6b63\u5e38\u9020\u8840\u529f\u80fd\u7684\u7834\u58de\u3002\u53ca\u65e9\u767c\u73fe\u75c7\u72c0\u53ef\u53ca\u6642\u9032\u884c\u5206\u5b50\u8a3a\u65b7\uff0c\u6709\u52a9\u65bc\u9032\u884c\u6a19\u9776\u6cbb\u7642\uff0c\u5927\u5927\u6539\u5584\u60a3\u8005\u7684\u9810\u5f8c\u60c5\u6cc1\u3002\u6211\u5011\u5f37\u70c8\u5efa\u8b70\u60a8\u53ca\u6642\u5411\u5c08\u9580\u7684\u816b\u7624\u79d1\u91ab\u7642\u6a5f\u69cb\u6c42\u8a3a\u3002<\/p>\n

                \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u5206\u671f\u8207\u5b58\u6d3b\u7387<\/h2>\n

                \u968e\u6bb5 1\uff1a\u6162\u6027\u968e\u6bb5<\/h3>\n

                \u6162\u6027\u968e\u6bb5\u7684\u7279\u9ede\u662f\u8840\u7d30\u80de\u589e\u751f\u76f8\u5c0d\u53d7\u5230\u63a7\u5236\uff0c\u6b63\u5e38\u8840\u6db2\u529f\u80fd\u7684\u640d\u5bb3\u6975\u5c0f\uff1a<\/p>\n

                  \n
                • \u7279\u5fb5\uff1a\u767d\u8840\u75c5\u7d30\u80de\u589e\u6b96\u7de9\u6162\u3002\u901a\u5e38\u60a3\u8005\u662f\u5728\u4f8b\u884c\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73fe\u5168\u8840\u7403\u8a08\u6578\u7570\u5e38\u800c\u88ab\u8a3a\u65b7\u51fa\u4f86\u3002<\/li>\n
                • \u6cbb\u7642\u9078\u64c7\uff1a\u7b2c\u4e00\u7dda\u6cbb\u7642\u901a\u5e38\u4f7f\u7528\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291 (TKIs)\uff0c\u5982 Imatinib\u3001Dasatinib \u6216 Nilotinib\uff0c\u5df2\u8b49\u5be6\u80fd\u9054\u5230\u986f\u8457\u7684\u75be\u75c5\u63a7\u5236\u6548\u679c\u3002<\/li>\n
                • \u5b58\u6d3b\u7387\uff1a\u6839\u64da\u9999\u6e2f\u767d\u8840\u75c5\u5b78\u6703(2024)\u6240\u6536\u96c6\u7684\u8cc7\u6599\uff0c\u82e5\u80fd\u53ca\u6642\u63a1\u53d6\u9069\u7576\u7684\u4ecb\u5165\u63aa\u65bd\uff0c\u4e94\u5e74\u5b58\u6d3b\u7387\u7d04\u70ba 90-95%\u3002<\/li>\n<\/ul>\n

                  \u7b2c\u4e8c\u968e\u6bb5\uff1a\u52a0\u901f\u968e\u6bb5<\/h3>\n

                  \u5728\u9019\u5927\u90e8\u4efd\u7684\u904e\u6e21\u968e\u6bb5\u4e2d\uff0c\u767d\u8840\u75c5\u7d30\u80de\u6703\u56e0\u70ba\u57fa\u56e0\u7a81\u8b8a\u7684\u7d2f\u7a4d\u800c\u8b8a\u5f97\u8d8a\u4f86\u8d8a\u591a\uff1a<\/p>\n

                    \n
                  • \u7279\u5fb5\uff1a\u9020\u8840\u4e2d\u5ea6\u81f3\u56b4\u91cd\u4e2d\u65b7\uff0c\u9aa8\u9ad3\u548c\u8840\u6db2\u4e2d\u672a\u6210\u719f\u7d30\u80de\u6bd4\u4f8b\u589e\u52a0\u3002<\/li>\n
                  • \u6cbb\u7642\u5347\u7d1a\uff1a\u4f7f\u7528\u5148\u9032\u7684\u4e8c\u7dda TKIs \u9032\u884c\u806f\u5408\u6cbb\u7642\uff0c\u4e26\u5bc6\u5207\u9032\u884c\u5206\u5b50\u76e3\u6e2c\u3002\u5176\u4ed6\u6cbb\u7642\u9078\u64c7\u5305\u62ec\u5316\u7642\u3001\u6a19\u9776\u6cbb\u7642\u6216\u8003\u616e\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d (HSCT)\u3002<\/li>\n
                  • \u5b58\u6d3b\u7387\uff1a\u64da\u7d71\u8a08\uff0c\u5982\u679c\u5728\u5c08\u79d1\u4e2d\u5fc3\uff08\u5982 MD Anderson \u806f\u71df\u6a5f\u69cb\u6216\u6df1\u5733 AllCancer \u4ee3\u8b1d\u816b\u7624\u4e2d\u5fc3\uff09\u5bc6\u5207\u7ba1\u7406\uff0c5 \u5e74\u7684\u5e73\u5747\u5b58\u6d3b\u7387\u7d04\u70ba 70-80%\u3002<\/li>\n<\/ul>\n

                    \u7b2c 3 \u968e\u6bb5\uff1a\u7206\u70b8\u5371\u6a5f\u968e\u6bb5<\/h3>\n

                    \u5728\u7206\u767c\u5371\u6a5f\u968e\u6bb5\uff0c\u4fb5\u7565\u6027\u7684\u767d\u8840\u75c5\u7d30\u80de\u589e\u6b96\u6703\u5927\u5e45\u7834\u58de\u6b63\u5e38\u7684\u8840\u6db2\u529f\u80fd\uff1a<\/p>\n

                      \n
                    • \u7279\u5fb5\uff1a\u6b63\u5e38\u9020\u8840\u529f\u80fd\u56b4\u91cd\u53d7\u640d\u3002\u8207\u6025\u6027\u767d\u8840\u75c5\u76f8\u4f3c\u7684\u7206\u88c2\u7d30\u80de\u589e\u52a0\uff0c\u6703\u986f\u8457\u964d\u4f4e\u6a19\u6e96\u7642\u6cd5\u7684\u7642\u6548\u3002<\/li>\n
                    • \u6cbb\u7642\u9078\u64c7\uff1a\u52a0\u5f37\u5316\u7642\u3001\u5206\u5b50\u9776\u5411\u7642\u6cd5\u3001\u7814\u7a76\u6027\u4ee3\u8b1d\u7642\u6cd5 (\u91dd\u5c0d\u65b0\u9673\u4ee3\u8b1d\u7684\u8106\u5f31\u6027\uff0c\u4f8b\u5982 Warburg \u6548\u61c9\u3001\u8461\u8404\u7cd6\u4f9d\u8cf4\u6027\u589e\u52a0\u3001\u8c37\u6c28\u9170\u80fa\u6eb6\u89e3)\u3002\u7acb\u5373\u9032\u884c\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u8a55\u4f30\u81f3\u95dc\u91cd\u8981\u3002<\/li>\n
                    • \u5b58\u6d3b\u7387\uff1a\u4e00\u822c\u800c\u8a00\uff0c\u6b64\u968e\u6bb5\u7684\u5b58\u6d3b\u7387\u6703\u986f\u8457\u4e0b\u964d\uff0c\u6839\u64da\u6700\u8fd1\u767c\u8868\u5728\u300a\u81ea\u7136\u91ab\u5b78\u300b(Li et al., 2024)\u4e0a\u7684\u7814\u7a76\uff0c\u4e09\u5e74\u5167\u5e73\u5747\u5b58\u6d3b\u7387\u70ba 20-40%\u3002<\/li>\n<\/ul>\n

                      \u7b2c 4 \u968e\u6bb5\uff1a\u665a\u671f\u8f49\u79fb\u6027\u5f71\u97ff<\/h3>\n

                      \u96d6\u7136\u8f49\u79fb\u8207\u5be6\u9ad4\u816b\u7624\u7684\u95dc\u4fc2\u8f03\u5927\uff0c\u4f46 CML \u7684\u56b4\u91cd\u5668\u5b98\u6d78\u6f64\u8207\u6b64\u985e\u4f3c\uff1a<\/p>\n

                        \n
                      • \u7279\u5fb5\uff1a\u767d\u8840\u75c5\u7d30\u80de\u5ee3\u6cdb\u6ef2\u5165\u4e3b\u8981\u5668\u5b98\uff0c\u5c24\u5176\u662f\u809d\u81df\u3001\u813e\u81df\u3001\u6dcb\u5df4\u7d50\uff0c\u5076\u723e\u4e5f\u6703\u6ef2\u5165\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\uff0c\u53cd\u6620\u51fa\u5be6\u9ad4\u816b\u7624\u4fb5\u7565\u6027\u7684\u5168\u8eab\u6027\u75be\u75c5\u3002<\/li>\n
                      • \u6cbb\u7642\u7b56\u7565\uff1a\u7a4d\u6975\u7684\u591a\u6a21\u5f0f\u7642\u6cd5\u3001\u65e8\u5728\u964d\u4f4e\u764c\u7d30\u80de\u8461\u8404\u7cd6\u4f9d\u8cf4\u6027\u7684\u4ee3\u8b1d\u7642\u6cd5\u7b56\u7565\u3001\u652f\u63f4\u6027\u8b77\u7406\uff0c\u4ee5\u53ca\u91cf\u8eab\u8a02\u505a\u7684\u76ee\u6a19\u6027\u7d44\u5408\u3002<\/li>\n
                      • \u5b58\u6d3b\u7387\uff1a\u5b58\u6d3b\u7387\u986f\u8457\u964d\u4f4e\uff0c\u4e09\u5e74\u5b58\u6d3b\u7387\u964d\u81f3\u7d04 20%\u3002\u53ca\u65e9\u5c31\u8a3a\u4ee5\u9032\u884c\u65b0\u9673\u4ee3\u8b1d\u7684\u4ecb\u5165\u6cbb\u7642\uff0c\u5c31\u50cf\u674e\u570b\u83ef\u91ab\u5e2b\u5275\u65b0\u6027\u5730\u9032\u884c\u7684\u90a3\u4e9b\u6cbb\u7642\uff0c\u53ef\u6709\u52a9\u65bc\u9054\u5230\u6709\u610f\u7fa9\u7684\u7a69\u5b9a\u3002<\/li>\n<\/ul>\n

                        \u5118\u7ba1\u5982\u6b64\uff0c\u65b0\u9673\u4ee3\u8b1d\u6cbb\u7642\u548c\u5148\u9032\u7684\u7642\u6cd5\u7d44\u5408\u6b63\u5728\u9010\u6b65\u6539\u8b8a\u9810\u5f8c\u7ba1\u7406\u3002\u6211\u5011\u7684\u816b\u7624\u5b78\u5c08\u5bb6\u6cbb\u7642\u4e86\u8d85\u904e 12,000 \u500b\u767d\u8840\u75c5\u75c5\u4f8b\uff0c\u9019\u4e9b\u65b0\u8208\u8b49\u64da\u548c\u5ee3\u6cdb\u75c5\u4f8b\u6a94\u6848\u4e2d\u7684\u75c5\u60a3\u6545\u4e8b\uff0c\u70ba\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7b2c 4 \u671f\u7684\u6162\u6027\u75c5\u6cbb\u7642\u5e36\u4f86\u4e86\u5be6\u8cea\u7684\u5e0c\u671b\u3002<\/p>\n

                        \u5340\u57df\u8003\u616e\u56e0\u7d20\uff1a\u9999\u6e2f\u8207\u4e9e\u6d32<\/h3>\n

                        \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u5728\u9999\u6e2f\u548c\u4e9e\u6d32\u4eba\u53e3\u4e2d\u7684\u6d41\u884c\u75c5\u5b78\u986f\u793a\u51fa\u7368\u7279\u7684\u6d41\u884c\u75c5\u5b78\u6a21\u5f0f\uff0c\u9019\u4e9b\u6d41\u884c\u75c5\u5b78\u6a21\u5f0f\u662f\u7531\u7368\u7279\u7684\u907a\u50b3\u50be\u5411\u3001\u751f\u6d3b\u65b9\u5f0f\u56e0\u7d20\u548c\u91ab\u7642\u4fdd\u5065\u57fa\u790e\u8a2d\u65bd\u6240\u9020\u6210\u7684\uff1a<\/p>\n

                          \n
                        • \u5340\u57df\u6d41\u884c\u7387\uff1a<\/strong> \u5728\u9999\u6e2f\uff0cCML \u767c\u75c5\u7387\u7d04\u70ba\u6bcf\u5e74\u6bcf 10 \u842c\u4eba\u4e2d 1-2 \u4f8b\uff0c\u8207\u53c3\u8003\u4e0a\u6d77\u8840\u6db2\u5b78\u7814\u7a76\u6240 (2024) \u7684\u4e9e\u6d32\u4eba\u53e3\u7d71\u8a08\u7814\u7a76\u4e00\u81f4\u3002<\/li>\n
                        • \u5e74\u9f61\u56e0\u7d20\uff1a<\/strong> \u4e3b\u8981\u8a3a\u65b7\u65bc 40-60 \u6b72\u7684\u75c5\u60a3\uff0c\u6bd4\u897f\u65b9\u4eba\u53e3\u7d71\u8a08\u4e2d\u5178\u578b\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u5e74\u8f15\u3002<\/li>\n
                        • \u91ab\u7642\u7167\u8b77\u7684\u5f71\u97ff\uff1a<\/strong> \u65e9\u671f\u816b\u7624\u6aa2\u6e2c\u53d7\u5230\u5168\u6e2f\u63a8\u884c\u7684\u5065\u5eb7\u6aa2\u67e5\u8a08\u5283\u7684\u91cd\u5927\u5f71\u97ff\uff0c\u4e26\u900f\u904e\u8207\u570b\u969b\u816b\u7624\u7db2\u7d61\uff08\u5982\u6df1\u5733\u524d\u6d77\u6cf0\u5eb7\u548c MD Anderson Cancer Center\uff09\u7684\u7a69\u5b9a\u5408\u4f5c\u9032\u4e00\u6b65\u52a0\u5f37\u3002<\/li>\n<\/ul>\n

                          \u7531\u65bc\u674e\u570b\u83ef\u535a\u58eb\u548c\u5289\u570b\u9f8d\u6559\u6388\u5728\u4ee3\u8b1d\u816b\u7624\u5b78\u9818\u57df\u64c1\u6709\u5148\u9032\u7684\u57fa\u790e\u8a2d\u65bd\u548c\u5c08\u696d\u5275\u65b0\u6280\u8853\uff0c\u9999\u6e2f\u53ca\u5468\u908a\u5730\u5340\u7684\u5c45\u6c11\u53ef\u5f9e\u53ca\u6642\u8a3a\u65b7\u548c\u5148\u9032\u6cbb\u7642\u4e2d\u7372\u76ca\u3002\u7a4d\u6975\u7684\u5065\u5eb7\u7ba1\u7406\u548c\u5229\u7528\u4ee3\u8b1d\u7684\u5f31\u9ede\u5f9e\u6839\u672c\u4e0a\u6539\u5584\u6162\u6027\u7c92\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u7684\u9810\u5f8c\uff0c\u986f\u8457\u63d0\u9ad8\u6574\u500b\u5730\u5340\u7684\u5b58\u6d3b\u7387\u3002<\/p>\n

                          \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6cbb\u7642\u65b9\u6848<\/h2>\n

                          \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6a19\u6e96\u91ab\u7642\u65b9\u6cd5<\/h3>\n

                          \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6cbb\u7642\u65b9\u6848\u5df2\u5927\u5e45\u6f14\u9032\uff0c\u9664\u4e86\u50b3\u7d71\u7642\u6cd5\u4e4b\u5916\uff0c\u9084\u63d0\u4f9b\u66f4\u65b0\u3001\u66f4\u6709\u91dd\u5c0d\u6027\u7684\u65b9\u6cd5\u3002\u4e3b\u8981\u7642\u6cd5\u5927\u81f4\u53ef\u5206\u70ba\u5316\u5b78\u6cbb\u7642\u3001\u6a19\u9776\u5206\u5b50\u6cbb\u7642\u3001\u653e\u5c04\u6cbb\u7642\u548c\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d (HSCT)\uff0c\u4e26\u4f9d\u64da\u75c5\u60a3\u5e74\u9f61\u3001\u75be\u75c5\u968e\u6bb5\u548c\u907a\u50b3\u7279\u5fb5\u500b\u5225\u91cf\u8eab\u6253\u9020\u3002<\/p>\n

                          \u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291 (TKIs)<\/h4>\n

                          \u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff0c\u7279\u5225\u662f\u4f0a\u99ac\u66ff\u5c3c (\u683c\u5217\u885b\u2122)\u3001\u9054\u6c99\u66ff\u5c3c (Sprycel\u00ae) \u548c\u5c3c\u6d1b\u66ff\u5c3c (Tasigna\u00ae) \u7684\u51fa\u73fe\uff0c\u70ba\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6cbb\u7642\u7b56\u7565\u5e36\u4f86\u4e86\u9769\u547d\u6027\u7684\u6539\u8b8a\u3002\u9019\u4e9b\u85e5\u7269\u91dd\u5c0d BCR-ABL \u878d\u5408\u86cb\u767d\u7684\u916a\u6c28\u9178\u6fc0\u9176\u6240\u5f15\u8d77\u7684\u8cbb\u57ce\u67d3\u8272\u9ad4\u6613\u4f4d\uff0c\u6709\u6548\u5730\u5728\u65e9\u671f\u968e\u6bb5\u963b\u6b62\u75be\u75c5\u60e1\u5316\u3002<\/p>\n

                            \n
                          • \u7b2c\u4e00\u4ee3 TKI\uff1aImatinib \u91dd\u5c0d BCR-ABL \u6fc0\u9176\uff0c\u7d04\u6709 75-85% \u7684\u5b8c\u5168\u7d30\u80de\u57fa\u56e0\u53cd\u61c9\u7387 (CCR)\u3002<\/li>\n
                          • \u7b2c\u4e8c\u4ee3 TKIs\uff1a\u9054\u6c99\u66ff\u5c3c (Dasatinib) \u8207\u5c3c\u6d1b\u66ff\u5c3c (nilotinib) \u5c0d\u6297\u8010\u85e5\u578b\u865f\u7684\u85e5\u529b\u66f4\u5f37\uff0c\u53ef\u9054\u5230\u66f4\u9ad8\u7684\u53cd\u61c9\u7387 (\u226585%)\uff0c\u4e26\u6539\u5584\u6162\u6027\u671f CML \u7684\u7642\u6548\u3002<\/li>\n
                          • \u7b2c\u4e09\u4ee3 TKIs\uff1aPonatinib (Iclusig\u00ae) \u80fd\u6709\u6548\u8655\u7406 T315I \u7b49\u8010\u85e5\u7a81\u8b8a\uff0c\u9019\u4e9b\u7a81\u8b8a\u666e\u904d\u5b58\u5728\u65bc\u96e3\u6cbb\u6027\u75c5\u4f8b\u4e2d\u3002<\/li>\n<\/ul>\n

                            \u81ea\u7136\u91ab\u5b78\u300b(Nature Medicine) \u671f\u520a\u767c\u8868\u7684\u7814\u7a76\u5f37\u8abf\uff0c\u500b\u4eba\u5316\u9078\u64c7 TKIs \u53ef\u63d0\u9ad8\u97ff\u61c9\u7387\uff0c\u8207\u8afe\u8c9d\u723e\u734e\u5f97\u4e3b Allison \u548c Semenza \u6240\u63d0\u5021\u7684\u5275\u65b0\u4e0d\u8b00\u800c\u5408\uff0c\u5c07\u500b\u4eba\u5316\u816b\u7624\u6cbb\u7642\u63a8\u5411\u5168\u4e9e\u6d32\u3002<\/p>\n

                            \u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d (HSCT)<\/h4>\n

                            \u7570\u57fa\u56e0\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d\u4ecd\u662f\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6f5b\u5728\u6cbb\u7642\u65b9\u6cd5\uff0c\u5c24\u5176\u662f\u5c0d TKIs \u8010\u85e5\u6216\u9032\u5c55\u81f3\u52a0\u901f\u671f\u6216\u7206\u767c\u671f\u7684\u60a3\u8005\u3002\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d\u4ee5\u5065\u5eb7\u7684\u6350\u8d08\u8005\u5e79\u7d30\u80de\u53d6\u4ee3\u75c5\u8b8a\u7684\u9aa8\u9ad3\uff0c\u70ba\u9577\u671f\u7684\u7de9\u89e3\u5e36\u4f86\u5e0c\u671b\u3002<\/p>\n

                              \n
                            • \u6700\u9069\u5408\u5e74\u8f15\u7684\u75c5\u60a3 (<55 years) with matched sibling or unrelated compatible donors.<\/li>\n
                            • \u7531\u65bc\u79fb\u690d\u7269\u6297\u5bbf\u4e3b\u75be\u75c5 (GvHD) \u548c\u56b4\u91cd\u611f\u67d3\u7684\u98a8\u96aa\u76f8\u7576\u9ad8\uff0c\u56e0\u6b64\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u9700\u8981\u8b39\u614e\u8a55\u4f30\u3002<\/li>\n
                            • \u5728\u9999\u6e2f\u7684\u91ab\u9662\uff0c\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d\u7684\u7d50\u679c\u986f\u793a\uff0c\u82e5\u80fd\u53ca\u6642\u4ecb\u5165\uff0c\u7d04\u6709 60-70% \u7684\u9577\u671f\u7de9\u89e3\u3002<\/li>\n<\/ul>\n

                              \u5316\u5b78\u6cbb\u7642\u548c\u653e\u5c04\u6cbb\u7642<\/h4>\n

                              \u96d6\u7136\u76ee\u524d\u5316\u7642\u548c\u653e\u5c04\u6cbb\u7642\u4e26\u975e\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u4e3b\u8981\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f46\u5728\u79fb\u690d\u6216\u65b0\u8208\u6cbb\u7642\u65b9\u6848\u4e4b\u524d\uff0c\u5b83\u5011\u53ef\u80fd\u6703\u5728\u665a\u671f\u75c5\u4f8b\u4e2d\u767c\u73fe\u6709\u9650\u7684\u61c9\u7528\uff0c\u4ee5\u8fc5\u901f\u63a7\u5236\u75be\u75c5\u9032\u5c55\u3002<\/p>\n

                                \n
                              • \u7fa5\u57fa\u8132 (Hydroxyurea) \u662f\u4e00\u7a2e\u5316\u7642\u85e5\u7269\uff0c\u53ef\u66ab\u6642\u4f7f\u5347\u9ad8\u7684\u767d\u8840\u7403\u8a08\u6578\u6062\u5fa9\u6b63\u5e38\uff0c\u6709\u52a9\u65bc\u75c7\u72c0\u7de9\u89e3\u3002<\/li>\n
                              • \u653e\u5c04\u6cbb\u7642\u4e3b\u8981\u662f\u5354\u52a9\u6e1b\u8f15\u9aa8\u75db\uff0c\u6216\u7e2e\u5c0f\u665a\u671f\u75c5\u4f8b\u7684\u813e\u81df\u5927\u5c0f\u3002<\/li>\n<\/ul>\n

                                \u65b0\u8208\u7684\u4ee3\u8b1d\u578b\u7642\u6cd5<\/h4>\n

                                \u674e\u570b\u83ef\u535a\u58eb\u548c\u5289\u570b\u9f8d\u6559\u6388\u7b49\u7814\u7a76\u4eba\u54e1\u901a\u904e\u6c83\u4f2f\u683c\u6548\u61c9\u548c\u8c37\u6c28\u9170\u80fa\u4f9d\u8cf4\u6027\u7a81\u986f\u4e86\u95dc\u9375\u7684\u4ee3\u8b1d\u8106\u5f31\u6027\uff0c\u4e26\u5c08\u6ce8\u65bc\u91dd\u5c0d\u764c\u7d30\u80de\u4ee3\u8b1d\u7684\u5275\u65b0\u7642\u6cd5\u3002\u963b\u65b7\u8461\u8404\u7cd6\u8f49\u904b\u9ad4 (GLUT1\/3) \u548c\u7834\u58de\u8c37\u6c28\u9170\u80fa\u65b0\u9673\u4ee3\u8b1d\u662f\u6700\u8fd1\u5728\u9802\u5c16\u671f\u520a\u4e0a\u767c\u8868\u7684\u7814\u7a76\u4e2d\u63d0\u5021\u7684\u65b0\u8208\u7b56\u7565\u3002<\/p>\n

                                  \n
                                • \u4ee3\u8b1d\u7642\u6cd5\u53ef\u964d\u4f4e\u8461\u8404\u7cd6\u5229\u7528\u7387\uff0c\u6291\u5236\u767d\u8840\u75c5\u7d30\u80de\u589e\u6b96\u3002<\/li>\n
                                • \u5728\u4e9e\u6d32\u6a5f\u69cb\u9032\u884c\u7684\u81e8\u5e8a\u524d\u7814\u7a76\u986f\u793a\u7642\u6548\u826f\u597d\uff0c\u70ba\u81e8\u5e8a\u8a66\u9a57\u92ea\u8def\u3002<\/li>\n<\/ul>\n

                                  \u500b\u4eba\u5316\u6cbb\u7642\u8a08\u5283\uff1a\u9999\u6e2f\u53ca\u4e9e\u6d32\u7684\u65b9\u6cd5<\/h3>\n

                                  \u7531\u65bc\u9999\u6e2f\u53ca\u4e9e\u6d32\u75c5\u4eba\u7684\u57fa\u56e0\u5dee\u7570\uff0c\u500b\u4eba\u5316\u6cbb\u7642\u7b56\u7565\u8b8a\u5f97\u975e\u5e38\u91cd\u8981\u3002\u4e9e\u6d32\u4eba\u5076\u723e\u6703\u51fa\u73fe\u4e0d\u540c\u7684\u6297\u85e5\u6027\u7a81\u8b8a\uff0c\u5f71\u97ff\u85e5\u7269\u7684\u7642\u6548\u3002\u56e0\u6b64\uff0c\u5148\u9032\u7684\u8a3a\u65b7\u5de5\u5177\uff08\u5982\u5168\u9762\u7a81\u8b8a\u7be9\u67e5\uff09\u53ef\u5f15\u5c0e\u9069\u7576\u7684\u500b\u4eba\u5316\u6cbb\u7642\u3002<\/p>\n

                                  \u9452\u65bc\u9019\u4e9b\u500b\u4eba\u5316\u7b56\u7565\u548c\u5168\u9762\u7684\u57fa\u56e0\u5206\u6790\uff0c\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u9810\u5f8c\u986f\u8457\u6539\u5584\uff0c\u5f37\u8abf\u65e9\u671f\u8a3a\u65b7\u548c\u91cf\u8eab\u8a02\u505a\u7684\u7ba1\u7406\u7b56\u7565\u3002<\/p>\n

                                  \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u50b3\u7d71\u7642\u6cd5\u7684\u9650\u5236<\/h2>\n

                                  \u8207\u5316\u7642\u548c\u653e\u5c04\u6cbb\u7642\u76f8\u95dc\u7684\u6311\u6230<\/h3>\n

                                  \u5118\u7ba1\u5316\u5b78\u7642\u6cd5\u548c\u653e\u5c04\u6cbb\u7642\u5728\u67d0\u4e9b\u60c5\u6cc1\u4e0b\u6709\u6548\uff0c\u4f46\u5b83\u5011\u7684\u526f\u4f5c\u7528\u6703\u4f7f\u4eba\u8870\u5f31\uff0c\u56b4\u91cd\u9650\u5236\u4e86\u5b83\u5011\u7684\u64f4\u5c55\u6548\u7528\u548c\u8010\u53d7\u6027\u3002\u4e00\u9805 JAMA Oncology 2023 \u5831\u544a\u5f37\u8abf\uff0c\u5316\u7642\u75c5\u60a3\u9aa8\u9ad3\u6291\u5236\u7684\u767c\u751f\u7387\u9ad8\u9054 78%\uff0c\u4f7f\u4ed6\u5011\u5bb9\u6613\u53d7\u5230\u4e8c\u6b21\u611f\u67d3\u548c\u8ca7\u8840\u3002<\/p>\n

                                    \n
                                  • \u5728\u63a5\u53d7\u50b3\u7d71\u5316\u7642\u65b9\u6848\u7684\u7d04 23% \u4e2d\u89c0\u5bdf\u5230\u5fc3\u81df\u6bd2\u6027\u3002<\/li>\n
                                  • \u9577\u671f\u98a8\u96aa\u5305\u62ec\u7e7c\u767c\u6027\u60e1\u6027\u816b\u7624\u7684\u6a5f\u7387\u986f\u8457\u589e\u52a0 (\u589e\u52a0 300%)\u3002<\/li>\n<\/ul>\n

                                    \u653e\u5c04\u6cbb\u7642\u96d6\u7136\u5f88\u5c11\u7528\u65bc\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)\uff0c\u4f46\u6703\u5e36\u4f86\u66f4\u9ad8\u7684\u98a8\u96aa\u56e0\u7d20\uff0c\u4f8b\u5982\u56b4\u91cd\u7684\u7d44\u7e54\u640d\u50b7\u548c\u7a81\u8b8a\u983b\u7387\u589e\u52a0\uff0c\u4f7f\u6f5b\u5728\u7684\u7e7c\u767c\u6027\u75be\u75c5\u4f75\u767c\u75c7\u60e1\u5316\u3002<\/p>\n

                                    \u624b\u8853\u98a8\u96aa\u8207\u9650\u5236<\/h3>\n

                                    \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u9664\u4e86\u7f55\u898b\u7684\u75c5\u4f8b\u5982\u813e\u81df\u5207\u9664\u8853\u4ee5\u6e1b\u8f15\u986f\u8457\u7684\u813e\u5927\u4f75\u767c\u75c7\u5916\uff0c\u5f88\u5c11\u6d89\u53ca\u76f4\u63a5\u7684\u624b\u8853\u4ecb\u5165\u3002\u624b\u8853\u7684\u8907\u96dc\u6027\u5305\u62ec<\/p>\n

                                      \n
                                    • \u7531\u65bc CML \u60a3\u8005\u7684\u514d\u75ab\u7cfb\u7d71\u53d7\u640d\uff0c\u624b\u8853\u5f8c\u611f\u67d3\u98a8\u96aa\u589e\u52a0\u3002<\/li>\n
                                    • \u56b4\u91cd\u7684\u8853\u5f8c\u4f75\u767c\u75c7\u53ef\u80fd\u6703\u5ef6\u9072\u5fc5\u8981\u7684\u5f8c\u7e8c\u6cbb\u7642\uff0c\u4f7f\u75be\u75c5\u7ba1\u7406\u8b8a\u5f97\u8907\u96dc\u3002<\/li>\n<\/ul>\n

                                      \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u4ee3\u8b1d\u62b5\u6297\u6a5f\u5236<\/h3>\n

                                      \u5728\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u665a\u671f\u75c5\u4f8b\u4e2d\uff0c\u7531\u65bc\u5176\u7368\u7279\u7684\u65b0\u9673\u4ee3\u8b1d\u9069\u61c9\u6027\uff0c\u50b3\u7d71\u6cbb\u7642\u5f80\u5f80\u6703\u9047\u5230\u6975\u5927\u7684\u6297\u85e5\u6027\u3002\u9019\u4e9b\u9069\u61c9\u5305\u62ec\u9ad8\u4ee3\u8b1d\u5f48\u6027\u548c DNA \u4fee\u5fa9\u9175\u7d20\u6d3b\u6027\u4e0a\u8abf (\u5728\u67d0\u4e9b\u7814\u7a76\u4e2d\u589e\u52a0\u7d04 400%)\u3002<\/p>\n

                                        \n
                                      • \u5c0d\u6cbb\u7642\u5e72\u9810\u7522\u751f\u7684\u6297\u85e5\u6027\u5927\u5e45\u964d\u4f4e\u6cbb\u7642\u6548\u679c\uff0c\u4f7f\u665a\u671f\u75be\u75c5\u7684\u5ba2\u89c0\u53cd\u61c9\u7387\u964d\u81f3 21% \u4ee5\u4e0b\u3002<\/li>\n
                                      • \u65b0\u8208\u7814\u7a76\u7a81\u986f\u764c\u7d30\u80de\u5728\u6cbb\u7642\u58d3\u529b\u4e0b\u7684\u4ee3\u8b1d\u6539\u9053\u80fd\u529b\uff0c\u5f37\u8abf\u8feb\u5207\u9700\u8981\u4ee3\u8b1d\u7279\u7570\u6027\u7684\u6a19\u9776\u6cbb\u7642\u85e5\u7269\u3002<\/li>\n<\/ul>\n

                                        \u9451\u65bc\u50b3\u7d71\u7642\u6cd5\u4e00\u76f4\u5b58\u5728\u660e\u986f\u7684\u7f3a\u9ede\uff0c\u52a0\u4e0a\u65b0\u9673\u4ee3\u8b1d\u6297\u85e5\u6a5f\u5236\u7684\u6578\u64da\u4e0d\u65b7\u589e\u52a0\uff0c\u9999\u6e2f\u53ca\u5468\u908a\u5730\u5340\u7684\u79d1\u5b78\u5bb6\u7a4d\u6975\u7814\u7a76\u5176\u4ed6\u5d84\u65b0\u7684\u6cbb\u7642\u65b9\u6cd5\uff0c\u4ee5\u5927\u5e45\u6539\u5584\u75c5\u4eba\u7684\u9810\u5f8c\u53ca\u751f\u6d3b\u8cea\u7d20\u3002<\/p>","protected":false},"excerpt":{"rendered":"

                                        \u5728 AllCancer \u63a2\u7d22\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u75c7\u72c0\u3001\u5206\u671f\u548c\u9769\u547d\u6027\u7684 HK \u4ee3\u8b1d\u7642\u6cd5\u3002<\/p>","protected":false},"author":3,"featured_media":7375,"parent":0,"menu_order":0,"template":"","class_list":["post-7724","cancer_type","type-cancer_type","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/cancer_type\/7724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/cancer_type"}],"about":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/types\/cancer_type"}],"author":[{"embeddable":true,"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/users\/3"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/media\/7375"}],"wp:attachment":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/media?parent=7724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}